@davistalkspepss
1 post audited · 6 claims analysed
Science evidence grade
Based on 6 claims across 1 audit
4
Supported
67%
0
Overstated
0%
0
Misleading
0%
2
No Evidence
33%
Share this evidence grade
Claim-level evidence grades — not a character judgment. Methodology · Right of reply · Leaderboards
What @davistalkspepss claims actually are
We separate claims into three buckets: backed by evidence, factually incorrect, and grey — like animal-only findings sold as human fact (e.g. BPC-157 “fixes Achilles” from rat studies).
Evidence-based
67%
4 claims
Claims that align with published human or clinical evidence at the stated strength.
Ex: “Semaglutide can reduce body weight in adults with obesity” — supported by large RCTs.
Factually incorrect
0%
0 claims
Claims that conflict with the evidence, invent certainty, or omit critical safety/context in a misleading way.
Ex: “Peptides have no side effects” — contradicts known adverse-event profiles.
Grey / overstated
33%
2 claims
Plausible direction but wrong certainty — animal-only data sold as human fact, dose/effect overstated, or no adequate published support yet.
Ex: “BPC-157 fixes Achilles tears” — often rests on rodent tendon models, not proven human Achilles repair trials.
Evidence mix
Share of audited claims in each bucket
Verdict detail
Grey splits into overstated (wrong certainty) vs no published support
Claims over time
Stacked by bucket as audits land — plus the running evidence grade
Gold line = running science evidence grade (Supported + ½ Overstated ÷ total claims).
Audit history(1 post)
“does tesa build muscle? here’s what the research says”
The creator's claims about tesamorelin's role in the GH-IGF-1 axis are scientifically supported. Tesamorelin is confirmed as a GHRH receptor agonist (Claim 1), with human clinical trial evidence demonstrating GHRH's effect on pituitary GH secretion (Claim 2). While Claims 3–4 lack specific evidence in the provided search results, they represent established endocrinological principles. Claim 5 (IGF-1 and muscle growth) is supported by human trial context and PeptIQ's reference literature. Claim 6 appropriately distinguishes tesamorelin as an indirect, step-one signaling molecule rather than a direct muscle builder—a mechanistically accurate and important clarification. The unverified 'Adrian et al., 2019' citation warrants correction, but the underlying claim remains sound.
Audit another post from @davistalkspepss
Paste their social post link to add a new audit